Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India: GlobalData | The Financial Express

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India: GlobalData

The company claims that the CKD market is mainly dominated by cheap, generic drugs, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, and beta blockers.

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India: GlobalData
Studies suggest there is a high prevalence of insulin resistance in India. (File)

GlobalData on Tuesday said that as India has a large population of diabetic patients, Bayer’s Kerendia can gain quick market penetration in the country. Recently, Bayer launched its first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, Kerendia (finerenone), for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in India.

GlobalData’s ‘Pharmaceutical Intelligence Center’ reveals that India had the highest number of diagnosed prevalent cases of T2D at 76.2 million among the 9MM countries (The US, France, Germany, Italy, Spain, the UK, Japan, China, and India) last year. The number is estimated to reach 91.7 million in 2029.

The company claims that the CKD market is mainly dominated by cheap, generic drugs, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, and beta blockers. Kerendia will benefit patients with moderate or severe kidney damage, who pass albumin (a type of protein) in their urine.

“The existing treatments for patients with CKD and diabetes in India majorly focus on preventing the end-stage renal disease or kidney failure. Yet, most of the patients progress to kidney failure and then require dialysis or renal transplant, which is a great economic burden. Thus, there is a huge unmet need for cost-effective treatment of CKD patients with diabetes,” Dr. Pavan Sunkireddy, Pharma Analyst at GlobalData, said in a statement.

Kerendia is expected to face stiff competition from sodium-glucose co-transporter (SGLT) inhibitors due to label expansion in CKD treatment. SGLT inhibitors, including Forxiga (dapagliflozin), were initially approved to treat T2D patients. According to reports, Forxiga is approved for CKD treatment in the country.

“Kerendia acts differently from the existing CKD in type2 diabetes treatments by blocking mineralocorticoid receptor (MR) activation and controlling CKD progression and cardiovascular damage. Hence, this drug can be a great opportunity to address the unmet need to treat CKD in diabetic patients in India. Given India’s huge population with diabetes and limited effective treatment for CKD, there is a great opportunity for Kerendia as it costs INR 97.5 ($ 1.23) per day,” Dr. Sunkireddy added.

ALSO READ | Olympus Corp’s plans of partnership with startups may strengthen MedTech industry: GlobalaData

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.